Introduction
Biological activity has the probabilistic nature, and the most appropriate approaches in activity prediction are based on the theory of probability. The statistical nature of maximum likelihood method and Bayesian approach is well recognized, but many other methods (multiple regression, factor analysis, pattern recognition methods such as linear discriminant analysis, linear learning machine, support vector machines etc.)
1-3 can also be considered as probabilistic ones. 4, 5 An informational search in PubMed Central with the queries "(probabilistic approach) OR (probabilistic method)" or "(statistical approach) OR (statistical method)", will find 3,477 documents or 180,475 documents, respectively. It is impossible to analyze all these publications, particularly taking into account that, despite of the presence of this term in their titles many of them are not really probabilistic (see, for instance, refs 6−20) . We propose the following definition of probabilistic approaches: "The methods that use probabilities as an essential part of the algorithm, and/or for which the results of application are presented as probability estimates". Thus, many approaches that do not correspond strictly to the definition, are not considered in this chapter. Since data on general dose-response relationships are not available in many cases, biological activity is often represented by a single quantitative or even qualitative characteristic. Therefore, many training sets are created with activity data presented in such mode. These probabilistic ligand-based drug design methods are further used for virtual screening. Existing training sets are not ideal, not just due to the simplified definition of biological activity, but also because (i) no one activity is represented by all relevant chemical classes and (ii) no one compound has been tested against all kinds of biological activity. So, the probabilistic character of biological activity is caused not only by experimental errors of its determination but also by incompleteness of available information.
Typically, virtual screening methods are used to select hits with a single required activity, [21] [22] [23] [24] while the final aim of pharmaceutical R & D is to identify safety and potent leads and drug-candidates. [25] [26] [27] [28] To overcome this problem, the authors have developed a method for prediction of many kinds of biological activity simultaneously based on the structural formula of chemical compound, which is realized in the computer program PASS (Prediction of Activity Spectra for Substances). 29, 30 PASS provides the means for evaluation of general biological activity profile at the early stages of R & D, and thus its prediction can be used as a basis for the selection of compounds with the required kinds of biological activity but without unwanted ones. 31, 32 In this chapter we overview some probabilistic methods used for biological activity prediction, paying particular attention to the problems of creation of the training and evaluation sets, validation of (Q)SAR models, estimation of prediction accuracy, interpretation of the prediction results and their application in virtual screening. characteristics. Certainly, this is a simplified definition because the exhibition of biological activity depends on the presence and state of the corresponding targets and experimental conditions (object, route of administration, dose, etc.). However, such approximation provides a possibility for combining of information from many different sources, which is necessary because no one particular publication represents comprehensively different aspects of biological action of a compound. For example, to collect information on the biological activity profile of caffeine discussed above, an extensive information search was performed of the available literature and databases.
Dose-Effect Relationships
In the most general form the description of biological activity of a certain chemical compound can be represented as a probability of occurrence of a certain biological response, depending on the experimental conditions (object, its state, means of exposure) and "dosage" of the compound ("dosage" can be represented in many different ways, in particular a single per os administration or fixed amount of a substance):
Test) Pr (Doze, . Under the fixed experimental conditions one obtains a simple relationship "dose-effect": ) ( Pr(Doze) D P  . It must be stressed that P(D) is the probability of occurrence of a certain effect, which depends on a dose D as a parameter.
According to the recommendations, 47 in quantitative measurements of biological activity drug action is expressed In experimental testing of toxicity the results are presented by the numbers of surviving (n) and dying (m) biological objects within the fixed period of time under the fixed doses of acting substance D. The conditional probability ) | , ( D n m P of certain numbers m and n at the certain D corresponds to the Bernoulli distribution: ; for instance if (i) the part of population is resistant to the acting compounds and (ii) the suggested threshold q exceeds the fraction of the responsible part of population.
In accordance with the probabilistic nature of the biological activity concept, the most relevant methods for prediction of activity are those based on probabilistic theory and mathematical statistics, and the purpose of prediction is the complete relationship
Unfortunately, in practice, the application of such approaches is strongly limited by the available experimental data, which in most cases are presented by semi-effective doses and even by qualitative characteristics "active/inactive". 51,52
Experimental Data
The determination of biological activity is always associated with some experimental errors, which may be caused by variability of biological objects, inaccuracy of measurements due to the limited precision of the used equipment, inaccuracy of the personnel doing manual and mental work.
If the experimental measurements have been repeated several times, the resultant data are presented as average values and standard deviations (SDs) of the measurements. In many cases numerical data in the literature and, particularly, in databases are presented without SDs even in cases where such values could be calculated on the basis of primary data. Also, the results of testing in high-throughput assays for inactive compounds typically mean that the compound does not cause the studied effect at a certain threshold, e.g., at 10 M, 1 M, etc. 52 Experimental errors associated with human error may be introduced both in experimental procedures (e.g., inaccuracies of sample preparation) and in theoretical analysis of the study results (e.g., errors in data drawing in publications, errors during the input of data into a computer).
As was concluded by Christoph Helma et al.: 53 After summarizing our experiences with the quality assurance of chemical data in predictive toxicology, we conclude that the currently available databases and computational chemistry programs are too faulty to be trusted without further inspection. The development of reliable quality control procedures definitely needs more discussion, exchange of experience, and research activity. In this sense, we hope that we will raise some awareness in regard to data quality issues and quality assurance in predictive toxicology.
The necessity of quality control for chemical structures, particularly when the data are aggregated from different sources, was recently emphasized in another publication. 54 However, the main source of scattering in experimental data is certainly determined by the variability of biological response. As was shown by comparison of results obtained in rodent carcinogenicity experiments, the concordance between the results taken from general literature and the results obtained from US National Toxicology
Program is only about 57%. 55 Therefore, the reproducibility of biological assays may be quite poor. It is well known that LD 50 values for rodents obtained in different laboratories may vary significantly (e.g., in LD 50 studies performed by eleven laboratories to standardize a type A botulinum toxin assay for accessing the toxin in food contaminations, up to a ten-fold difference in results was shown). 56 Notably, in actual practice training sets are not ideal: in addition to a simplified definition and high variability of biological activity they do not contain all chemical classes relevant to a particular biological activity, and information about all kinds of biological activity that can be revealed by a particular compound is always incomplete (no one compound is tested against all kinds of biological activity, and there is no one activity for which all possible ligands are known). Consequently, the probabilistic character of biological activity is caused not only by experimental errors of its determination but also by the incompleteness of available information.
Probabilistic Ligand-Based Virtual Screening Methods
Virtual screening methods are based on the modeling of the biological phenomenon of molecular recognition, either by the principle of complementarity or by the principle of similarity. 57 Probabilistic ligand-based virtual screening methods look rather simple and fast; however, for their successful application it is necessary to have a training set of compounds with known activity. Probabilistic methods are based on the achievements of machine learning and have a long history, starting from pattern recognition methods. 4, 5, [58] [59] [60] [61] [62] [63] Especially for the purposes of drug design, probabilistic methods were developed by Golender and Rozenblit, 64 and realized later in the expert system OREX. 65 In Section 6.4 we describe in detail the probabilistic method developed by our team, and to which the methods 7, [66] [67] [68] [69] [70] [71] [72] [73] [74] and binary QSAR 51, 52, 75, 76 are rather close in basic characteristics.
An important component of probabilistic ligand-based virtual screening methods is the design of the training set, which is the set of ligands available or selected to develop the virtual screening system. [77] [78] [79] [80] [81] The selection of this set and its usage strongly influence the overall performance of the final system. 82, 83 Also, it is necessary to use the appropriate evaluation of prediction accuracy and reliability, and the representation and interpretation of biological activity prediction results is very important. Based on the probabilistic approach, it is possible to solve all these problems.
Preparation of Training Sets
Training sets should be representative for the compounds to be classified by the ligand-based virtual screening system. 83 Virtual screening is usually performed on a set containing a large number of ligands with a high diversity of molecular structure. For successful results, the diversity of structures from the training set must be comparable to those from the corresponding set used for virtual screening. As a rule, any training set must include sufficient active compounds as well as inactive ones. It seems obvious that an "ideal" training set must include all tested active and inactive compounds. However, in practice it is necessary to be very careful during the design of training set because "a data set consisting of database chemical drawings and HTS assay measurements may be very misleading". 52 There exist some other peculiarities, for instance every compound in the MDDR database (MDL® Drug Data Report 84 ) has one or several records in the field "activity class", indicating that the compound is related to a certain therapeutic area. However, because of "umbrella patents", not each substance in MDDR was actually tested in biological assays. Those substances for which biological activity was studied in detail are called "principal compounds", and they have some records in the field "Action", such as experimental data on activity, LD 50 , IC 50 , K i , etc. There are some publications, in which the training set is prepared on the basis of the MDDR database but this peculiarity is not taken into account. 7, 73, 74, [85] [86] [87] In these publications, for each ligand from the training sets that was actually tested in biological assays there are several structurally similar molecules for which biological activity was assigned with the purpose of umbrella patenting. Therefore, unsurprisingly, structure similarity methods studied in these publications were shown to be rather successful during the validation.
In a well-designed training set the structural diversity must be as uniform as possible. It is very difficult to control such uniformity; however, the presence of closely similar compounds series in the set could (and have to) be checked, to avoid degeneracy.
In general, any ligand-based virtual screening method is based on direct or generalized similarity between the screened compound and compounds from the training set. Therefore, if such similarity is absent at all, no reasonable prediction of screened compound's properties can be made by using this training set.
Creation of Evaluation Sets
There are two fundamental problems in ligand-based virtual screening systems development: model selection and performance estimation. Almost invariably, all ligand-based methods have one or more adjustable parameters. To select the "optimal" parameter(s) or model for a given classification problem, it is necessary to utilize the independent evaluation set that was not used in the training procedure. Once the predictive system is developed, to estimate its performance, one must utilize the test set that was not used during the development process. To obtain the precise estimation of system performance, the test set must be large, ideally infinite. However, for a good choice of a model or its parameter(s), the number of compounds in training and evaluation sets must also be large. For theoretical analysis one can subdivide all available data into two (training and test) or three (training, evaluation and test) sets, which have to be approximately equal in size. However, to develop the actual working virtual screening system one must used all available data for the training; therefore, nothing remains for the evaluation and test sets. To overcome this contradiction, the most suitable methods for construction of evaluation (test) sets are K-Fold Cross-Validation (KF CV) and Leave-One-Out Cross-Validation (LOO CV). [87] [88] [89] [90] To perform KF CV a K-fold partition of the data set is created. For each from К experiments, K-l folds are used for training and the remaining one for testing. The true error estimate is obtained as the average of the separate К estimates. LOO CV is the degenerated case of KF CV, where К is chosen as the total number of examples. For a data set with N examples, perform N experiments, for each experiment use N-1 examples for training and the remaining one example for testing. The true error is estimated as the average error value on test examples -on all existing examples. Vapnik 4 proved several theorems, which stated unbiasedness and consistency of LOO CV estimation, if LOO CV is carefully performed: no information about the excluded compound is used for training and tuning the system based on a residual part of data set. Unfortunately, in the general case the computational time for LOO CV or even for KF CV will be very large due to the large number of sequential experiments. Fortunately, the probabilistic approaches usually have a small or zero number of tuned parameters and the LOO CV procedure can be performed quite easily. Thus, all available data can be used both for training and for evaluation of probabilistic ligand-based virtual screening systems. Earlier we have shown 91 that LOO CV provides a more rigorous accuracy estimation than the repeated many times 2-Fold (or jack-knife) CV.
Mathematical Approaches
Many different methods can be applied to virtual screening, and such methods are described in other chapters of this book and/or in the Handbooks of Che-minformatics. 3 Here we discuss the methods based on a probabilistic approach. Unfortunately, there are many publications in which the "probabilistic" or "statistical" approach items are farfetched. The Binary Kernel Discrimination [8] [9] [10] 17, 20 and the Bayesian Machine Learning Models 6 are actually special cases of Artificial Neural Networks; whereas the Probabilistic Neural Networks [14] [15] [16] are really similaritybased methods, which do not take into account the results of well-developed nonparametric regression methods. 92 In virtual screening of the chemical structures set called the Screening Set (SS) for each compound CSS any proposed method P should give the estimate P(C), which, being compared with a certain criterion, provides the basis for decision about the advisability of further testing of the chemical compound C. In other words, it is necessary to recognize whether compound С belongs to the class of compounds in which we are interested in, i.e., to solve the task of pattern recognition (PR), which is a typical problem of Machine Learning (ML). There are a lot of publications, monographs and specialized journals devoted to the problems of ML and PR; machine learning approaches are widely used in cheminformatics (see, for example, refs. 11, 67, [69] [70] [71] 73, 87, 93, 94) . Notably, the fundamentals of machine learning were developed much earlier than the informational technologies (IT) became 61 noted, referring to Kanal, 59 that the engineers rediscover for themselves well-known methods of statistics. Later, in machine learning these methods were discovered for a second time, and now the same situation is observed in cheminformatics: methods well known to engineers and IT specialists are rediscovered once again. Mathematically, the estimate P(C) in many cases can be represented as: It is widely accepted that probabilistic approach was first developed and applied in expert systems MYCIN 95, 96 and PROSPECTOR. 97 In these expert systems the likelihood estimates are calculated for several competitive hypo- When applied to virtual screening the naive Bayes classifier consists in the following.
Let a molecular structure of compound }, and the probability that it belongs to a given class A is estimated by a conditional probability
Using Bayes' theorem, we write: 
As a result, the log-likelihood ratio of the conditional probability   
and using Bayes' theorem for
In terms of the general formula (6.3) The describing functions 
shape coincides with the shape of 
Evaluation of Prediction Accuracy
When a classifier that provides the estimation of P(C) is constructed, its performance must be estimated. The most important estimation is of the prediction accuracy. To do this, an evaluation set (test set or validation set -see Section 6.3.2) must be used. The evaluation set (ES) must be relevant and include both type of examples -positive and negative ("active" and "inactive" compounds). For all compounds  C ES estimations P(C) are calculated, and obtained values are analyzed using knowledge about the "true" classification of compounds in ES. Figure 6 .4 shows the main features of this task.
Let us suggest that for compounds in ES we have values of some targeted molecular property. "Expert" divides ES into two parts: positive and negative examples. Using a constructed estimator we calculate P(C) values and, selecting the threshold value, divide ES into two other parts: predicted positive if It is important to keep in mind that the situation illustrated in Figure 6 .4 is a common case and it has symmetry in relation to errors: errors can be both in estimations P(C) and in experimental values. The result like that shown in Figure 6 . 4 109 Youden's index summarizes the test accuracy into a single numeric value, Sensitivity + Specificity -1, or:
The recognition accuracy estimation described above faces one very important problem: what is the best choice for the threshold value  ? To solve this problem, statistical decision theory is used. FP, TN and FN) possible results. If a priori probabilities or losses are not known, the optimal choice is MiniMax (Mimimizing the Maximum possible loss) according to which the optimal threshold value must satisfy the condition "Sensitivity = Specificity". Another choice may be the maximum of Youden's index.
In any case, this approach uses several additional assumptions. For this reason in the last time in ML the recognition accuracy criterion of the Area Under the ROC Curve (AUC), which is free of additional assumptions, becomes very popular. 7, 63, [68] [69] [70] [71] [106] [107] [108] [112] [113] [114] [115] [116] Mathematically, AUC equals the probability that the estimation ) (C P assigns the higher value to a randomly drawn positive example  C than to the randomly drawn negative example In our papers 91, 117 we have used the Invariant Accuracy of Prediction ( IAP ) criterion, which exactly coincides with AUC , and it is calculated as: it is possible to compare the accuracy of several classifiers using ES with "errors of the teacher" correctly.
The IA ( IAP , AUC )) criterion gives a robust estimation of general classifiers performance, but in the case of virtual screening to find several ligands at a top of ranked compounds list, the minimal number of decoys may be more important. 116 
Single-Targeted vs. Multi-Targeted Virtual Screening
Most existing virtual screening methods have been developed to be used for selection of hits with a single targeted activity. [22] [23] [24] However, most discovered pharmaceutical agents have several or even many kinds of biological activity. Some of these biological activities represent adverse/toxic effects, some others can be considered as a reason for utilization of known medicines according to new indications, which is called repositioning of drugs.
123-126
Both new pharmacotherapeutics and adverse/toxic effect can be discovered on the basis of computer predictions with probabilistic methods. Different methods can be applied either sequentially or simultaneously. Early attempts to predict many kinds of biological activity simultaneously using such an approach were performed by Avidon and co-authors, 127 Golender and Rozenblit, 64, 65 and Vassiliev and co-authors. 128 Since the early 1990s, the authors have been developing the computer program PASS, which predicts many kinds of biological activity based on the structural formula of a compound. 29, 30, 32, 40, 41, 43, 100 This program, the present version of which predicts over 3000 kinds of biological activity with a mean accuracy of about 95%, is described in more detail below. Different PASS applications in virtual screening of multi-targeted ligands have been presented in several publications. [100] [101] [102] [103] [104] 129 The Prous Institute for Biomedical Research 130 is developing a computational method based on a wide range of molecular descriptors and binding profiles, called BioEpisteme ® , which is claimed to facilitate the discovery of new medicines and new uses for existing drugs. Pre-requisites of the BioEpisteme approach are quite close to the PASS concept: "A drug may interact with multiple targets and produce more than one therapeutic response and/or adverse effect." Unfortunately, we could not find a detailed description of the method used in BioEpisteme in the available literature -only the very general scheme presented on the web-site. 130 Recently, the number of different molecular mechanisms covered by BioEpisteme was reported to be about 400.
131
Quantum Pharmaceuticals 132 recently proposed a new method for toxicity prediction based on computation of small molecules' affinity to about 500 human proteins. The analysis of binding profiles for about 1000 known pharmaceutical agents led to establishment of a relation between the toxicological properties of a molecule and its activity against the selected representatives of approximately 50 protein families. This activity profile was further used as a "natural" set of descriptors for various toxicological endpoints predictions, including human-MRDD, human-MRTD, human-TDLo, mouse-LD 50 (oral, intravenous, subcutaneous), rat-LD 50 (oral, intravenous, subcutaneous, intraperitoneal), etc. 46 Thus, probabilistic biological activity prediction methods can be used for both estimation of adverse/toxic effects in molecules under study and for finding the multi-targeted ligands, which might "yield drugs of superior clinical value compared with monotargeted formulations". 33 
PASS Approach
The computer program PASS was designed to predict many kinds of biological activity simultaneously based on the structural formulae of chemical compounds. Thus, PASS may estimate the biological activity profiles for virtual molecules, prior to their chemical synthesis and biological testing.
Biological Activities Predicted by PASS
The latest version of PASS (2007) In PASS biological activities are described qualitatively ("active" or "inactive"). Qualitative presentation allows integrating information concerning compounds tested under different terms and conditions and collected from many different sources, as in the general PASS training set. Any property of chemical compounds that is determined by their structural peculiarities can be used for prediction by PASS. Clearly, the applicability of PASS is broader than the prediction of biological activity spectra. For example, we used this approach to predict drug-likeness 134 and the biotransformation of drug-like compounds. 
Chemical Structure Description in PASS
The 2D structural formulae of compounds were chosen as the basis for description of chemical structure because this is the only information available in the early stage of research. Plenty of characteristics of chemical compounds can be calculated on the basis of structural formulae. 3, 67, [136] [137] [138] [139] Earlier 29 we applied the Substructure Superposition Fragment Notation (SSFN) codes. 140 But SSFN, like many other structural descriptors, reflects rather abstraction of chemical structure by the human mind than the nature of the biological activity revealed by chemicals. The Multilevel Neighborhoods of Atoms (MNA) descriptors 91, 141, 142 have certain advantages over SSFN. These descriptors are based on the molecular structure representation, which includes the hydrogens according to the valences and partial charges of present atoms and does not specify the types of bonds. MNA descriptors are generated as a recursively defined sequence:
 zero-level MNA descriptor for each atom is the mark A of the atom itself;
 any next-level MNA descriptor for the atom is the sub-structure notation   ... ... 
SAR Base
The PASS estimations of biological activity spectra of new compounds are based on the Structure-Activity Relationships data and knowledge-base (SAR Base), which accumulates the results of the training set analysis. The in-house developed general PASS training set currently (December 2007) includes about 117000 known biologically active substances (drugs, drug-candidates, leads, and toxic compounds). Since new information about biologically active compounds is discovered regularly, we perform a special informational search and analyze the new information, which is further used for updating and correcting the PASS training set.
Algorithm of Activity Spectrum Estimation
The algorithm of activity spectrum estimation is based on the above-mentioned Bayesian approach, but differs in The main purpose of PASS is the prediction of activity spectra for new, possibly not yet synthesized compounds. Therefore, the general principle of the PASS algorithm is the exclusion from SAR Base of substances that is equivalent to the substance under prediction. So, if molecule n is equivalent to the molecule under prediction then this substance is excluded from sums in (Equations 6.17a,b) . for selection of probable activities, the chance to confirm the predicted activities by the experiment is high too, but many activities will be lost. For instance, if >80% is used as a threshold, about 80% of real activities will be lost;
for a P >70%, the portion of lost activities is 70%, etc.
An example of prediction results for sulfathiazole is shown in Figure 6 .6. This substance was found in SAR Base and was excluded from the SAR Base on prediction of its activity spectrum. The known (contained in SAR Base of PASS version 2007) activity spectrum includes the following activities: antibacterial, antibiotic, dihydropteroate synthase inhibitor, iodide peroxidase inhibitor. In Figure 6 .6 the predicted activity spectrum includes 65 of 374 pharmacological effects, 176 of 2755 molecular mechanisms, 7 of 50 side effects and toxicity, 11 of 121 metabolism terms at default Leave one out cross-validation for 3300 kinds of biological activity and 117332 substances provides the estimate of PASS prediction accuracy during the training procedure. The average accuracy of prediction is about 94.7% according to the LOO CV estimation, while that for particular kinds of activity varies from 65% [System lupus erythematosus treatment, Immunomodulator (HIV)] to 99.9%) (Allergic rhinitis treatment, histone acetylation inducer). The estimated accuracy of prediction for all kinds of biological activity predicted by PASS is presented at the web site. 143 The accuracy of PASS predictions depends on several factors, of which the quality of the training set seems to be the most important (Section 6.3.1). A perfect training set should include comprehensive information about biological activities known or possible for each compound. In other words, the whole biological activity spectrum should be thoroughly investigated for each compound included into the PASS training set. Actually, no database exists with information about biologically active compounds tested against each kind of biological activity. Therefore, information concerning known biological activities for any compound is always incomplete. We investigated the influence of the information's incompleteness on the prediction accuracy for new compounds. About 20000 "principal compounds" from the MDDR database (Section 6.3.1) were used to create the heterogeneous training and evaluation sets. At random, 20, 40, 60, 80% of information were excluded from the training set. Either structural data or biological activity data were removed in two separate computer experiments. In both cases it was shown that even if up to 60% of information is excluded the results of prediction are still satisfactory. 91 Thus, despite the incompleteness of information in the training set, the method used in PASS is robust enough to get reasonable prediction results. 
Interpretation of Prediction Results
Only activities with i a P P  are considered as possible for a particular compound.
It is necessary to remember that probability If, for instance, a P equals to 0.9, then for 90% of "actives" from the training set the В values are less than for this compound, and only for 10% of "actives" is this value higher. If we decline the suggestion that this compound is active, we will make a wrong decision with probability 0.9.
If a P is less than 0.5, but i a P P  then for more than half of "actives" from the training set the В values are higher than for this compound. If we decline the suggestion that this compound is active, we will make a wrong decision with a probability of <0.5. In such a case the probability of confirming this kind of activity in the experiment is small, but there is a more than 50% chance that this structure has a high degree of novelty and may become a New Chemical Entity (NCE).
If the predicted biological activity spectrum is wide, the structure of the compound is quite simple, and does not contain peculiarities that are responsible for the selectivity of its biological action.
If it appears that the structure under prediction contains a few new MNA descriptors (in comparison with the descriptors from the compounds of the training set), then the structure has low similarity with any structure from the training set, and the results of prediction should be considered as very rough estimates.
Based on these criteria, one may choose which activities have to be tested for the studied compounds on the basis of a compromise between the novelty of pharmacological action and the risk of obtaining a negative result in experimental testing. Certainly, one will also take into account a particular interest in some kinds of activity, experimental facilities, etc.
Selection of the Most Prospective Compounds
A fundamental limitation must be kept in mind: any observation, estimation or calculation has only restricted accuracy. In absolutely all cases instead of the desirable unknown intrinsic Real value we have only:
This is critically important for (virtual) screening especially. To highlight this, Figure 6 .8 presents the generated data of 1000 points with binormal distribution and correlation coefficient square R 2 = 0.95 and R 2 = 0.5. Clearly, for It is possible to perform a complete analysis of such relationships, but even the presented data provide enough evidence for the following conclusion: the method for (virtual) screening must be highly accurate, and/or many different virtual screening methods must be used in combination and/or the number of selected candidates must be sufficiently large at all stages of screening (in Figures 6.9 and 6 .10, the number 100 is not "sufficiently large"). 99, 116, 144, 145 
Conclusions
Since the predicted with PASS biological activity spectra contain the estimates of probabilities for the pharmacological main and side effects, molecular mechanisms of action and specific toxicity, the choice of the most prospective compounds from the available samples of chemical compounds can be realized on the basis of complex criteria. Both the presence of targeted biological effects with desirable mechanisms of action and the absence of unwanted adverse effects and toxicity have to be taken into account. In such studies, the search for leads with the required properties and their optimization to decrease the adverse and toxic effect, usually performed sequentially, will be solved simultaneously. Moreover, it was shown that the algorithms used in PASS can be successfully applied for discrimination between the so-called drug-like and drug-unlike compounds, 134 which provides the possibility for extension of the applicability of the program by "filtering" in early stages chemical compounds, for which probability of becoming a drug is rather small. The evolution of any molecule from hit to lead and from lead to drug-candidate typically is associated with the detailed evaluation of pharmacodynamics and pharmacokinetics of the compound. Using several different probabilistic methods for virtual screening together it might be possible to increase significantly the rate of promising substances in the selected subset. 101, 103 A challenging task is to optimize simultaneously both pharmacodynamics and pharmacokinetics of lead compounds because it is very difficult to modify the appropriate molecular determinants that define the desired compound characteristics in a consistent manner. However, even this task might be solved using "an integrated software framework that monitors ligand (or library) alterations in the context of 'fitness landscape"". 26 
